Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine
Behrokh Farahmand,
Mona Sadat Larijani,
Fatemeh Fotouhi,
Alireza Biglari,
Rahim Sorouri,
Fahimeh Bagheri Amiri,
Ali Eslamifar,
Tahmineh Jalali,
Mostafa Salehi-Vaziri,
Mohammad Banifazl,
Sarah Dahmardeh,
Azita Eshratkhah Mohammadnejad,
Anahita Bavand,
Mahsa Tavakoli,
Vicente Verez-Bencomo,
Ehsan Mostafavi,
Hassan Noori Daloii,
Fatemeh Ashrafian,
Masoumeh Saberpour,
Amitis Ramezani
Affiliations
Behrokh Farahmand
Department of Influenza and Other Rrespiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
Mona Sadat Larijani
Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran
Fatemeh Fotouhi
Department of Influenza and Other Rrespiratory Viruses, Pasteur Institute of Iran, Tehran, Iran; Corresponding author. Department of Influenza and other Rrespiratory Vviruses, Pasteur Institute of Iran, Tehran, No:69, Pasteur Ave, 1316943551, Iran.
Alireza Biglari
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Rahim Sorouri
IPI Directorate, Pasteur Institute of Iran, Tehran, Iran
Fahimeh Bagheri Amiri
Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran
Ali Eslamifar
Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran
Tahmineh Jalali
COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran
Mostafa Salehi-Vaziri
COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran
Mohammad Banifazl
Iranian Society for Support of Patients with Infectious Disease, Tehran, Iran
Sarah Dahmardeh
Vaccination Department, Pasteur Institute of Iran, Tehran, Iran
Azita Eshratkhah Mohammadnejad
Department of Influenza and Other Rrespiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
Anahita Bavand
Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran
Mahsa Tavakoli
COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran
Vicente Verez-Bencomo
Finlay Vaccine Institute, Havana, Cuba
Ehsan Mostafavi
Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran
Hassan Noori Daloii
Health and Safety Department, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran
Fatemeh Ashrafian
Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran
Masoumeh Saberpour
Department of Influenza and Other Rrespiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
Amitis Ramezani
Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran; Corresponding author. Clinical Research Department, Pasteur Institute of Iran, No:69, Pasteur Ave, Tehran, 1316943551, Iran.
COVID-19 pandemic has been managed through global vaccination programs. However, the antibody waning in various types of vaccines came to notice. Hereby, PastoCovac Plus as a protein subunit vaccine was investigated in immunized health care workers by COVAXIN (BBV152). The booster vaccine was recommended at least three months post the second dose of COVAXIN. Sera collection was done before and after each injection. SARS-CoV-2 PCR test was done monthly to detect any asymptomatic and symptomatic vaccine breakthrough.47.9 and 24.3% of the participants were seronegative for anti-N and anti-S antibodies three months after the second dose of COVAXIN, respectively. On average, fold-rises of 70, 93, 8 and mean-rises of 23.32, 892.4, 5.59 were recorded regarding neutralizing antibody, quantitative and semi-quantitative anti-Spike antibody, respectively. Anti-Spike and neutralizing antibodies seroconversion was seen 59.3% and 45.7%, respectively. The vaccine breakthrough assessment showed that all the isolated samples belonged to SARS-CoV-2 Delta variant. PastoCovac Plus boosting is strongly recommended in combination with inactivated vaccine platforms against SARS-CoV-2.
